Tildrakizumab Efficacy and Impact on Quality of Life Up to 52 Weeks in Patients with Moderate-to-Severe Psoriasis: A Pooled Analysis of Two Randomized Controlled Trials Psoriasis Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me